Cold-sores combo product
This article was originally published in The Gray Sheet
Executive Summary
Framingham, Mass.-based Transport Pharmaceuticals begins Phase III trial of iontophoretic drug-delivery device May 31. The study, designed to test the combination product's ability to treat cold sores with a single drug application, is scheduled to enroll 1,800 patients at 24 U.S. sites and will be considered complete when 200 patients in each of the three study arms have been treated. One patient group will receive the device and acyclovir 5% cream, another will be treated with the device via placebo cartridge, and a third with conventional cream therapy. The device administers topical acyclovir using Transport's low-voltage wireless electrode and medication applicators. Supported by GlaxoSmithKline, the trial is planned to conclude in 2006 (1"The Gray Sheet" Jan. 31, 2005, p. 25)...